Shares of pharmaceutical company Amarin (AMRN - Get Report) were up more than 7% in trading Thursday after the company's Vascepa drug was added to the American Diabetes Association's Standards of Medical Care in Diabetes list for 2019.
The drug, along with a specialized diet, has been shown to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. Amarin has agreed to give the Food and Drug Administration data to support the ADA's finding in order expand Vascepa's FDA label to include its recommendation.
"As we have commenced transmission of data to the FDA for the submission of our sNDA seeking an expansion of the Vascepa label based on the landmark REDUCE-IT results, we are pleased by ADA's acknowledgement of the importance of the REDUCE-IT results in its 2019 update of the Standards of Care," said Dr. Craig B. Granowitz, senior vice president and chief medical officer of Amarin.
Amarin said that Vascepa works without raising bad cholesterol when a four-gram dose is taken daily.
How Much Money Will I Need to Retire?
Want to learn about retirement planning from some of the nation's top experts? Join TheStreet's Robert "Mr. Retirement" Powell live in New York on April 6 for our Retirement Strategies Symposium. For a limited time, tickets are available for $99 for this full-day event. Check out the agenda, learn about the speakers and sign up here.